Bristol-Myers Squibb Company 8-K 2009
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 23, 2009
BRISTOL-MYERS SQUIBB COMPANY
(Exact Name of Registrant as Specified in its Charter)
345 Park Avenue
New York, NY, 10154
(Address of Principal Executive Office)
Registrants telephone number, including area code: (212) 546-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
On December 23, 2009, Bristol-Myers Squibb Company (the Company) completed the previously announced split-off of its 83.1 percent ownership in Mead Johnson Nutrition Company (Mead Johnson) to tendering shareholders of the Company. The split-off was effected through the exchange of the Companys previously held 170 million shares of Mead Johnson Nutrition Company for 269,285,601 outstanding shares of the Companys stock. The exchange offer was over subscribed.
A copy of the joint press release of the Company and Mead Johnson announcing the completion of the divestiture is attached hereto as Exhibit 99.1.
On December 23, 2009, the Company issued a press release announcing that it is updating its previously disclosed full year 2009 earnings per share from continuing operations guidance. A copy of the press release is furnished as Exhibit 99.2 to this report and incorporated herein by reference.
(b) Pro Forma Financial Information
The Companys unaudited pro forma financial information as required under Rule 11-01 of Regulation S-X is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.